BaseSpace
Correlation Engine 2.0
Import Your Data
QuickView

FAQ

More QuickView FAQs

Back to top
Clear Search sequence regions
(e.g. rs6983267, PBX1, Fatty acid metabolic process, Inflammatory disorder, Pancreas)
Bookmark Forward

QuickView for EDA2R;jsessionid=E10958033198F1D4407FD5100F9BBB26;jsessionid=DBE6283F7BAA28E3DC8C5BC1B8231157;jsessionid=9CA7C984AA822CFACF56CECF3DD9298A (gene)


Body Atlas

Most Correlated Tissues

  1. Superior cervical ganglion
  2. Skeletal muscle psoas
  3. Atrioventricular node
  4. Appendix
  5. Tongue
Explore Body Atlas Results

Disease Atlas

Most Correlated Diseases

  1. Hyperoxia
  2. Muscle atrophy
  3. Alpha-1-antitrypsin deficiency
  4. Steinert myotonic dystrophy syndrome
  5. Viremia
Explore Disease Atlas Results

Pharmaco Atlas

Most Correlated Compounds

  1. furan
  2. direct black 3
  3. E6 protein, Human papillomavirus type 18
  4. nutlin-3A
  5. 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one
Explore Pharmaco Atlas Results

Knockdown Atlas

Most Correlated Gene Perturbations

  1. MIR7-1
  2. ZRSR2
  3. LAMA2
  4. FRG1
  5. NEB
Explore Knockdown Atlas Results

Curated Studies

Most Correlated Studies

Loading...
Explore Curated Studies Results

Literature

Most Relevant Literature

  1. EDA2R-NIK signalling promotes muscle atrophy linked to cancer cachexia.
  2. Knockdown of EDA2R alleviates hyperoxia-induced lung epithelial cell injury by inhibiting NF-κB path…
  3. EDA2R mediates podocyte injury in high glucose milieu.
  4. Macrophage-derived EDA-A2 inhibits intestinal stem cells by targeting miR-494/EDA2R/β-catenin signal…
  5. Single-Nucleus Transcriptional Profiling of Chronic Kidney Disease after Cisplatin Nephrotoxicity.
Explore Literature Results

Clinical Trials

Most Relevant Clinical Trials

There were no clinical trials for EDA2R;jsessionid=E10958033198F1D4407FD5100F9BBB26;jsessionid=DBE6283F7BAA28E3DC8C5BC1B8231157;jsessionid=9CA7C984AA822CFACF56CECF3DD9298A
Explore Clinical Trials Results
  • Copyright © 2024 Illumina Inc. All rights reserved.